Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access Poster presentation

Antimicrobial use prior as a risk factor for developing extended-spectrum beta-lactamse-producing Klebsiella spp. in South Brazil

T Ostroski1*, C Ito2, C Busato1, MD da Rocha3, C da Silva4, V Bian5 and L Bail2

  • * Corresponding author: T Ostroski

Author Affiliations

1 Departamento de Medicina, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil

2 Análises Clínicas e Toxicológicas, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil

3 Departamento de Saúde Pública, Universidade Estadual de Ponta Grossa, Ponta Grossa, Brazil

4 Intensive Care Unit, Santa Casa de Misericórdia, Ponta Grossa, Brazil

5 Pharmacy, Santa Casa de Misericórdia, Ponta Grossa, Brazil

For all author emails, please log on.

BMC Proceedings 2011, 5(Suppl 6):P138  doi:10.1186/1753-6561-5-S6-P138

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/5/S6/P138


Published:29 June 2011

© 2011 Ostroski et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction / objectives

Extended-spectrum beta-lactamase-producing (ESBL) Klebsiella spp. is a problematic nosocomical pathogen around the world. In the present study, we aimed to evaluate the previous use of antibiotics as a risk factor for isolation of ESBL Klebsiella spp.

Methods

In a retrospective case control study between June 2009 and June 2010 at Santa Casa de Misericórdia Hospital, city of Ponta Grossa, south Brazil, 61 Klebsiella spp. (29 ESBL and 32 controls non-ESBL-producing isolates) were enrolled. ESBL were screened by disk diffusion method and double disk approximation method, according to CLSI. Prior use of antibiotic was analyzed in electronic medical records. The antibiotic consumption (DDDs – defined daily doses) was tested using the X2 test (p <0.05).

Results

The DDDs of prior use and full use of cephalosporines, fluoroquinolones, e metronidazole in ESBL and non-ESBL groups were (122.02/145.77; 8.78/69.07), (15.66/22; 0.01/26.2), (47.33/47.66; 3/28) respectively. Prior use of cephalosporines, fluoroquinolones, and metronidazole was higher in ESBL-Klebsiella spp. than non-ESBL-Klebsiella spp. (p<0,001). Carbapenems were not used by the control group.

Conclusion

Theprior use of broad-spectrum cephalosporins, fluoroquinolones and metronidazole is an important risk factor for acquisition of ESBL producing Klebsiella spp.

Disclosure of interest

None declared.